Literature DB >> 2298495

TIL from renal-cell carcinoma: restimulation with tumor influences proliferation and cytolytic activity.

J Alexander1, P Rayman, M Edinger, R Connelly, R Tubbs, R Bukowski, E Pontes, J Finke.   

Abstract

TIL were cultured from human renal-cell carcinoma (RCC) in 1,000 U/ml rIL2 and restimulated with autologous tumor in efforts to establish which conditions would best expand the number of lymphocytes cytotoxic for autologous tumor. Greater cell yields resulted from multiple restimulations of TIL with autologous tumor. In most instances, these TIL lysed autologous tumor better than TIL grown in rIL2 alone. Enhanced proliferation was seen also after restimulation of TIL with allogeneic RCC as well as with tumor cells of non-renal origin. Although in some instances lysis of autologous tumor appeared to be specific, restimulation with autologous tumor did not consistently result in the generation of specific cytolytic T cells. Attempts to culture more specific cytolytic T cells by using 50 U/ml rIL2 were successful in expanding TIL with enhanced lytic activity; however, this activity was not specific for autologous tumor. The phenotype of the tumor-restimulated TIL generally did not change. In most of the TIL cultures, CD3+CD4+ cells were predominant with low numbers of CD3+Leu19+ cells and minimal numbers of CD3-Leu19+ cells. Thus, the cytotoxic response to tumor was mediated by T cells and not NK cells. Overall, our data indicate that restimulation of TIL with autologous tumor may be beneficial for growing larger numbers of cells which have increased lytic activity and for prolonging the presence of lytic activity among the expanded TIL.

Entities:  

Mesh:

Year:  1990        PMID: 2298495     DOI: 10.1002/ijc.2910450121

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.

Authors:  M Dohlsten; G Hedlund; E Akerblom; P A Lando; T Kalland
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

3.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991

4.  Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.

Authors:  A Gorter; K M Krüse; P I Schrier; G J Fleuren; R J van de Griend
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

5.  T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.

Authors:  P A Lando; M Dohlsten; G Hedlund; E Akerblom; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

6.  Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.

Authors:  D Mitropoulos; S Kooi; J Rodriguez-Villanueva; C D Platsoucas
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

7.  Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity.

Authors:  H Naganuma; E Halapi; G Masucci; M Hansson; P Wersäll; C Hising; S Venkateswaran; H Mellstedt; R Kiessling
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

8.  Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation.

Authors:  Y Umezu; L B Augustus; D Seito; K Hayakawa; M I Ross; O Eton; D A Swanson; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

9.  The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.

Authors:  G G Steger; R Kaboo; J B deKernion; R Figlin; A Belldegrun
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.